Improving the efficiency of gas exchange during alimentary biocorrection of the nutritional status of students and teachers of an engineering university

The results of studies of alimentary correction of the efficiency of gas exchange in the lungs by the example of students and teachers of an engineering university with daily use of foods with known bio-correcting properties: 3.5 g of wheat germ oil (WGO), 50 g of wheat germ meal cake (WGMC), are presented 6.5 g of concentrated tissue fish oil (CTFO) and their combinations with the biomass of the consortium of lacto- and bifidobacteria (10 g). The efficiency of gas exchange processes was evaluated based on the analysis of the respiratory coefficient, the concentration of carbon dioxide (CO2) and oxygen (O2) in the exhaled gas mixture was determined using a TESTO-310 gas analyzer, an MDG-1201 capnograph, the values of which were recorded before and after daily use of the studied products during 30 days. The experimental group consisted of volunteers – teachers and university students aged 16 to 65 years, divided into 3 age groups: 16-24, 25-44 and 45-65 years old. It was established that the most effective antihypoxic drug is WGMC, in all age groups, the increase in average RR values amounted to 0.041 units, and 4.8% relative to the initial values. When using WGO, the change in RC was 0.032, an increase compared to baseline – 3.7%. In the 1st, 2nd and 3rd age groups, the average change in RC was: 0,031, 0,036 and 0,043 units, relative to the initial indicators, the increase was 3.5, 4.2 and 5.0%, respectively. It is proved that the combination of the studied biocorrector with the active forms of probiotic microorganisms provides a more active antihypoxic effect for all the studied products in all age groups. The effectiveness of the WGO was increased, the increase in RC was 0.049 units, for CTFO – 0.024 units. The growth of RC relative to the initial values was 5.7 and 2.9%, respectively. The synergism of the action of biocorrectors in combination with probiotics, by age groups amounted to – 0.035, 0.033 and 0.038 units, which is 4.1, 3.8 and 4.5% relative to the initial indicators

Data from: Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia

Background. NTZ is approved in Russia for the treatment of highly active relapsing remitting multiple sclerosis and is reimbursed via federal budget program. However, no data about NTZ treatment in Russia and the effect of federal reimbursement have been performed so far. Objective. To characterize the population of patients receiving natalizumab and assess the efficacy and risk-management plan (RMP) implementation of NTZ therapy in routine clinical practice in Russia. Methods. We analyzed data for 334 patients, who received at least one infusion of NTZ. Relapse rate, MRI activity, NEDA-3 status after 2 years were assessed. Anti-JC virus antibodies status and RMP implementation were evaluated. Drop-out rate and reasons for therapy discontinuation were analyzed. Results. Patients switched to natalizumab in Russia are mainly female (63%), with median EDSS score of 3.5 and high disease activity: 93% had at least 1 relapse and 58% had both T1Gd+ and new T2 lesion an year before therapy initiation. Introduction of federal reimbursement allowed to start therapy with natalizumab for patients with less relapses. The only predictor of 6-month progression was EDSS score at the baseline of therapy (HR=2.1375, 95%CI 1.0026 – 4.5570, p=0.0492). 82% patients reached NEDA-3 at 24 month of therapy. 25% of patients discontinued NTZ for reasons: tolerability (14.5%), JCV antibody status (61%), and patient’s decision (17%). RMP was implemented in only 36% patients. Conclusion. Natalizumab appeared to have high efficacy in Russian clinical practice. Federal reimbursement allowed less active patients to start natalizumab. More efforts should be done to improve RMP implementation